Let's break down Pfizer Ltd. (PFIZER) — from its financial performance to how the market is valuing the stock.
Pfizer Revenue Trend
Pfizer Ltd.'s top line grew 3.4% to ₹2,454 Cr in FY2025, compared to ₹2,374 Cr in FY2024.
On a 10-year view, revenue grew from ₹1,853 Cr to ₹2,454 Cr at a 2.8% CAGR — slow growth that may signal a maturing business.
Pfizer Ltd. is a mid-sized pharmaceuticals company by revenue, with a top line of ₹2,454 Cr.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹2,454 Cr | +3.4% |
| FY2024 | ₹2,374 Cr | -6.0% |
| FY2023 | ₹2,526 Cr | -5.5% |
| FY2022 | ₹2,674 Cr | +15.3% |
| FY2021 | ₹2,320 Cr | — |
View Pfizer Ltd.'s full 10-year revenue trend with CAGR analysis →
Pfizer Profitability
The bottom line looked healthy: Pfizer Ltd. posted net profit of ₹768 Cr in FY2025, 39.2% above FY2024.
Net margin widened to 31.3% in FY2025 — an improvement from the 23.2% recorded in FY2024.
Diluted EPS stood at ₹167.79 in FY2025, compared to ₹120.51 in FY2024.
Is Pfizer Undervalued
Under the P/E Ratio approach, Pfizer Ltd.'s estimated fair value is ₹5,421 (21.4% upside).
Pfizer Ltd. shares are currently trading at ₹4,465.50.
Craytheon also calculates intrinsic value using the EPS Growth and DCF models. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹5,421 | 21.4% upside to fair value |
| EPS Growth | Upgrade | Upgrade |
| DCF | Upgrade | Upgrade |
See all valuation models for Pfizer Ltd. with detailed assumptions →
Pfizer Shareholding Pattern
Promoters continue to hold 63.9% of the company, unchanged over recent quarters.
As of March 2026, FIIs own 2.8% of the company — up from 2.4% a year earlier.
Domestic institutional investors (DIIs) held 16.9% as of March 2026, down from 17.2% a year ago.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 63.9% | 2.8% | 16.9% | 16.4% |
| Dec 2025 | 63.9% | 2.7% | 17.1% | 16.3% |
| Sep 2025 | 63.9% | 2.6% | 17.1% | 16.4% |
| Jun 2025 | 63.9% | 2.4% | 17.2% | 16.4% |
Track quarterly shareholding changes for Pfizer Ltd. →
Pfizer Balance Sheet
Proportional view as of 3 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
In FY2025, the total asset base came in at ₹49.11B, up 16.1% YoY from ₹42.29B.
Cash & ST Investments accounts for 57.0% of the total, ahead of Other Assets (14.5%) and Intangibles & Goodwill (11.2%).
Capital structure: 85.9% equity, 2.2% debt, 11.9% operating liabilities. Over the year, debt is up 14.7% and equity is up 17.3%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 28.01B |
| Receivables | 1.93B |
| Inventories | 4.76B |
| Property, Plant & Equipment | 1.79B |
| Intangibles & Goodwill | 5.52B |
| Other Assets | 7.10B |
| Category | Value |
|---|---|
| Equity | 42.17B |
| Short-term Debt | 407.80M |
| Long-term Debt | 676.20M |
| Trade Payables | 1.52B |
| Other Liabilities | 4.34B |
Pfizer Stock Analysis
Here's the bottom line on Pfizer Ltd. (PFIZER) based on the latest available financials.
Revenue of ₹2,454 Cr in FY2025, up 3.4% year-over-year.
Long-term revenue has been compounding at 2.8% annually over 10 years.
The company is profitable, with a net margin of 31.3% and net income of ₹768 Cr.
The P/E Ratio model implies 21.4% upside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
There's more to the story. Craytheon's full profile for Pfizer Ltd. includes three valuation models, decade-long financials, and insider activity.